ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In the OPTIC trial, patients with CP-CML and resistance to ≥2 prior TKIs or ABL1 T315I mutation were initially dosed at ponatinib 45 or 30 mg/day and their dose reduced to 15 mg/day at time of CCyR [27].